XSHG
600521
Market cap3.72bUSD
Oct 09, Last price
17.45CNY
1D
4.80%
1Q
3.62%
Jan 2017
-4.96%
IPO
84.07%
Name
Zhejiang Huahai Pharmaceutical Co Ltd
Chart & performance
P/E
97.87
P/S
3.06
EPS
0.18
Div yield, %
1.50%
Shrs. gr., 5y
0.41%
Rev. gr., 5y
5.66%
Revenues
8.54b
-10.56%
Net income
267m
-76.14%
CFO
1.23b
-43.38%
Dividend
Jun 18, 20260.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.
Key people
Hong Li
Chairman of the Board · since 2019
Qimao Chen
Vice President · since 2007
Dunyuan Chen
Vice President · since 2017
Hui Gang
Vice President · since 2022
Xiaofang Kong
Vice President · since 2024
Lihong Lin
Vice President · since 2022
Mi Xu
Vice President, General Manager - International Sales Center · since 2022
Bo Xu
Vice President · since 2013
Mei Zhang
Chief Financial Officer, Senior Vice President · since 2022
Yanhua Meng
Vice President, General Manager - API Division · since 2022
Yonghua Zhu
Vice President, Secretary of the Board, Director · since 2007
Baohua Chen
President, Director · since 2019
Sijia Guo
Executive Vice President, Director · since 2022
Director · since 2013
Yan Su
Director · since 2007
Independent Director · since 2025
Gang Li
Independent Director · since 2022
Independent Director · since 2022
Headquarters & legal address
浙江省临海市汛桥
台州市, ZJ 100000
CN
台州市, ZJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||